Gyre Therapeutics IncNASDAQ:GYRE
- LAST PRICE17.1100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 17.1100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GYRE |
|---|---|---|
| 09:32 ET | 2322 | 16.33 |
| 09:34 ET | 1264 | 16.175 |
| 09:36 ET | 1200 | 16.1 |
| 09:38 ET | 1615 | 15.98 |
| 09:41 ET | 3189 | 16.06 |
| 09:43 ET | 1704 | 15.9 |
| 09:52 ET | 1776 | 16.1 |
| 09:54 ET | 300 | 16.09 |
| 09:56 ET | 800 | 16 |
| 09:57 ET | 400 | 16.16 |
| 09:59 ET | 300 | 16.16 |
| 10:01 ET | 2756 | 16.22 |
| 10:03 ET | 2111 | 16.2 |
| 10:06 ET | 1300 | 16.11 |
| 10:08 ET | 300 | 16.175 |
| 10:10 ET | 2027 | 16.05 |
| 10:12 ET | 847 | 16.11 |
| 10:14 ET | 395 | 16.16 |
| 10:15 ET | 1645 | 16.2 |
| 10:17 ET | 200 | 16.215 |
| 10:19 ET | 400 | 16.22 |
| 10:21 ET | 200 | 16.22 |
| 10:24 ET | 200 | 16.21 |
| 10:26 ET | 200 | 16.22 |
| 10:28 ET | 400 | 16.2 |
| 10:30 ET | 150 | 16.2 |
| 10:33 ET | 3327 | 16.33 |
| 10:35 ET | 300 | 16.33 |
| 10:37 ET | 791 | 16.39 |
| 10:39 ET | 100 | 16.39 |
| 10:42 ET | 3431 | 16.53 |
| 10:44 ET | 300 | 16.52 |
| 10:46 ET | 300 | 16.5 |
| 10:48 ET | 755 | 16.49 |
| 10:50 ET | 1079 | 16.4982 |
| 10:51 ET | 4082 | 16.62 |
| 10:53 ET | 4681 | 16.6778 |
| 10:55 ET | 2107 | 16.77 |
| 10:57 ET | 200 | 16.765 |
| 11:00 ET | 1600 | 16.765 |
| 11:02 ET | 2858 | 16.865 |
| 11:04 ET | 100 | 16.87 |
| 11:06 ET | 400 | 16.865 |
| 11:08 ET | 1294 | 16.92 |
| 11:09 ET | 100 | 16.92 |
| 11:11 ET | 510 | 16.915 |
| 11:13 ET | 200 | 16.915 |
| 11:15 ET | 6455 | 16.97 |
| 11:18 ET | 300 | 16.955 |
| 11:20 ET | 300 | 16.93 |
| 11:22 ET | 200 | 16.935 |
| 11:24 ET | 2651 | 16.98 |
| 11:26 ET | 1465 | 16.93 |
| 11:31 ET | 1634 | 16.96 |
| 11:33 ET | 5433 | 17.085 |
| 11:36 ET | 1000 | 16.99 |
| 11:42 ET | 100 | 16.995 |
| 11:44 ET | 400 | 16.98 |
| 11:45 ET | 200 | 16.975 |
| 11:47 ET | 100 | 16.98 |
| 11:49 ET | 200 | 16.98 |
| 11:54 ET | 1000 | 16.8444 |
| 11:56 ET | 200 | 16.975 |
| 11:58 ET | 500 | 16.98 |
| 12:00 ET | 200 | 16.975 |
| 12:03 ET | 100 | 16.95 |
| 12:05 ET | 100 | 16.96 |
| 12:07 ET | 200 | 16.975 |
| 12:09 ET | 400 | 16.98 |
| 12:16 ET | 300 | 16.98 |
| 12:18 ET | 100 | 16.98 |
| 12:20 ET | 600 | 16.98 |
| 12:23 ET | 3509 | 17.03 |
| 12:25 ET | 400 | 17.09 |
| 12:27 ET | 300 | 17.09 |
| 12:30 ET | 2706 | 17.17 |
| 12:32 ET | 4323 | 17.2499 |
| 12:34 ET | 4524 | 17.1401 |
| 12:38 ET | 2191 | 17.055 |
| 12:39 ET | 800 | 17.055 |
| 12:48 ET | 1796 | 17.07 |
| 12:50 ET | 6545 | 17.085 |
| 12:59 ET | 400 | 17.05 |
| 01:08 ET | 200 | 16.94 |
| 01:10 ET | 400 | 17.055 |
| 01:12 ET | 200 | 17.055 |
| 01:15 ET | 300 | 17.06 |
| 01:17 ET | 200 | 17.05 |
| 01:19 ET | 2983 | 17.11 |
| 01:26 ET | 300 | 17.1 |
| 01:28 ET | 200 | 17.085 |
| 01:32 ET | 400 | 17.09 |
| 01:35 ET | 466 | 17.085 |
| 01:37 ET | 300 | 17.1 |
| 01:42 ET | 200 | 17.095 |
| 01:46 ET | 1538 | 17.12 |
| 01:50 ET | 195 | 17.12 |
| 01:51 ET | 200 | 17.12 |
| 01:55 ET | 2281 | 17.07 |
| 01:57 ET | 200 | 17.11 |
| 02:02 ET | 400 | 17.105 |
| 02:06 ET | 200 | 17.11 |
| 02:08 ET | 200 | 17.105 |
| 02:11 ET | 1740 | 17.11 |
| 02:13 ET | 400 | 17.17 |
| 02:15 ET | 200 | 17.165 |
| 02:18 ET | 200 | 17.165 |
| 02:22 ET | 200 | 17.165 |
| 02:24 ET | 100 | 17.17 |
| 02:26 ET | 1379 | 17.17 |
| 02:27 ET | 900 | 17.08 |
| 02:29 ET | 1228 | 17.065 |
| 02:33 ET | 5529 | 17.12 |
| 02:36 ET | 1810 | 17.16 |
| 02:38 ET | 300 | 17.225 |
| 02:40 ET | 100 | 17.225 |
| 02:42 ET | 200 | 17.225 |
| 02:44 ET | 100 | 17.225 |
| 02:45 ET | 100 | 17.23 |
| 02:47 ET | 100 | 17.225 |
| 02:49 ET | 100 | 17.205 |
| 02:51 ET | 100 | 17.21 |
| 02:54 ET | 100 | 17.21 |
| 02:56 ET | 3019 | 17.23 |
| 02:58 ET | 800 | 17.25 |
| 03:00 ET | 100 | 17.25 |
| 03:02 ET | 200 | 17.25 |
| 03:03 ET | 639 | 17.23 |
| 03:05 ET | 4100 | 17.08 |
| 03:09 ET | 1925 | 17.07 |
| 03:20 ET | 1406 | 17.06 |
| 03:25 ET | 100 | 17.125 |
| 03:27 ET | 2526 | 17.17 |
| 03:30 ET | 100 | 17.165 |
| 03:32 ET | 100 | 17.145 |
| 03:34 ET | 100 | 17.145 |
| 03:36 ET | 100 | 17.145 |
| 03:38 ET | 200 | 17.15 |
| 03:39 ET | 2198 | 17.105 |
| 03:41 ET | 1600 | 17.055 |
| 03:48 ET | 356 | 17.15 |
| 03:52 ET | 300 | 17.15 |
| 03:54 ET | 200 | 17.15 |
| 03:56 ET | 2418 | 17.11 |
| 03:57 ET | 1567 | 17.11 |
| 03:59 ET | 2435 | 17.11 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gyre Therapeutics Inc | 1.5B | -0.8x | --- |
Neumora Therapeutics Inc | 1.5B | -3.9x | --- |
Kura Oncology Inc | 1.5B | -9.4x | --- |
Edgewise Therapeutics Inc | 1.5B | -10.3x | --- |
Morphic Holding Inc | 1.4B | -8.0x | --- |
Akero Therapeutics Inc | 1.4B | -6.9x | --- |
Company Information
Gyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in the research, development, manufacturing and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase III trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase I trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.
Contact Information
- Headquarters
- 12770 High Bluff Drive, Suite 150SAN DIEGO, CA, United States 92130
- Phone
- 619-949-3681
- Fax
- 302-636-5454
Executives
- Non-Executive Chairman of the Board
- Ying Luo
- President, Director
- Songjiang Ma
- Chief Executive Officer, Director
- Han Ying
- Interim Chief Financial Officer
- Ruoyu Chen
- Chief Operating Officer
- Weiguo Ye
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 85.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.06 |
EPS | $-20.60 |
Book Value | $4.62 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
